pm et
summari develop manufactur distribut continu glucos monitor system
nm price-to-earnings oper ep
risk assess reflect fact
produc sell one product although compani
littl debt yet gener annual net incom
compani face formid competit much
larger compani primarili
feb ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra keep hold
lift target
base discount cash flow
model assum five-year forward
compound annual growth rate revenu
ep vs
higher estim rais ep
estim ep
estim sale increas
year-over-year million
includ first full quarter sale
monitor cgm sale grew
year-over-year million
intern revenu grew
million think could achiev
revenu growth vs origin
expect growth albeit lower
margin custom mix shift
toward medicar intern market
continu invest heavili develop
second gener devic track
commerci releas earli
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
overview found aim address need diabet design
manufactur market continu glucos monitor cgm product potenti
enabl peopl diabet achiev sustain glycem control would help reduc
diabetes-rel health issu intern diabet feder estim million adult
year age live diabet number rise million
receiv approv first gener cgm
march receiv fda approv gener cgm call
signific enhanc predecessor elimin need finger stick
calibr confirm blood glucos level second cgm without finger stick
approv fda first freestyl libr flash approv
dxcm object becom lead provid cgm system relat product compani
focus develop commerci product integr cgm technolog insulin deliveri
system partner dxcm partner insulin deliveri includ tandem
busi segment one oper segment compani primarili focus
design develop commerci cgm system primarili deriv revenu
fiscal unit state revenu outsid grew year-over-year
reach million fy million fy percentag total revenu revenu
outsid increas fy fy fy
competit landscap market blood glucos monitor devic highli competit
constantli chang substanti impact introduct new product enhanc
sell platinum mobil system compet directli larg conglomer
roch diagnost johnson johnson abbot laboratori panason healthcar hold
also manufactur market product single-point finger stick devic collect
compani make global sale self-monitor glucos test system regard
short-term continu intermitt flash glucos monitor devic primarili compet
inc
collabor agreement verili life scienc research organ jointli
develop seri next-gener cgm product see aggress explor extend
product portfolio categori peopl diabet includ type diabet
non-insulin use peopl pre-diabet peopl obes develop gener
collabor product fulli dispos real-tim cgm system expect complet end
smaller cost-effect gener system expect introduc
believ effort could yield signific competit advantag
merger acquisit made recent signific acquisit
financi trend revenu grow rapidli year end
compani three-year cumul annual growth rate compound-annual-growth-rate year-over-year revenu
growth invest heavili research develop spent averag
revenu compani gener maintain net cash posit
howev incur oper loss sinc incept oper margin vs
meanwhil loss per share vs loss
respect decemb million gross defer
tax asset howev uncertain compani abl realiz asset
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
neutral sinc novemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
posit macro environ addit
sub-industri mani product area
histor recession-resist
particularli equip use non-elect
procedur valuat continu high
industri driven expand margin
robust revenu growth compani
industri think lax food
drug administr fda
increas capabl technolog
enabl medic devic manufactur bring
innov product market faster
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess head wind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
septemb retaliatori tariff
billion us medic technolog export
although us chines govern
seek lower health care cost provid
equip manufactur insul
industri earlier commentari
medic devic manufactur suggest
impact trade war would manag
provid commentari impact
trade war earn
on-going threat state health
care system current us
administr continu attempt repeal
afford act stop
multipl time gather suffici
number vote pass variou repeal
replac bill recent on-going
lawsuit texa question
constitution
think import watch
mid-term elect novemb
health care appear import topic
hospit spend larg driver medic
equip sale robust
strong us economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index increas vs rise
 composit index year
date septemb
increas composit
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra keep hold opinion share inc
lift target base discount
cash flow model assum five-year forward compound annual growth rate
revenu ep vs higher
estim rais ep estim ep
estim sale increas year-over-year
million includ first full quarter sale recent launch
continu glucos monitor cgm sale grew year-over-year
million intern revenu grew million
think could achiev revenu growth vs origin
expect growth albeit lower margin custom mix shift
toward medicar intern market continu invest heavili
develop second gener devic track commerci
releas earli /kevin huang cfa
et cfra upgrad opinion share inc hold
sell rais target base
discount cash flow model suggest trade near
fair valu ep vs higher estim
lower ep rais ep
sale increas year-over-year million driven
primarili sale continu glucos monitor cgm launch
happen week origin expect revenu
growth high-end manag guidanc growth
stellar think could grow albeit
substanti lower margin compani priorit meet custom demand
manufactur effici believ impact launch
freestyl libr cgm instead pressur sale
anticip boost overal awar demand cgm technolog /kevin
sell opinion set price target base
discount cash flow model suggest trade premium
set loss per share estim loss vs
loss yet gener annual profit
although think prosper growth opportun rapid
growth market continu glucos monitor cgm believ
opportun alreadi captur dxcm current share price
set launch latest cgm us market late june
view tradit abl charg premium
product technolog superior howev competitor
market compar believ consum becom price
sensit think price pressur could weigh
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
